Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 3/2019

15.03.2019 | Correspondence

Plasmablastic Lymphoma Versus EBV-Positive Myeloma

verfasst von: Divya Bansal, Neha Singh, Narendra Agrawal, Anurag Mehta

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Excerpt

Hematolymphoid neoplasms with plasmablastic lymphoma (PBL) and plamablastic/anaplastic myeloma (PBM) show significant morphological and/or immunophenotypic overlap which may make it very difficult for pathologists to make a definite and specific histopathological diagnosis [1]. Features such as renal dysfunction, significant paraprotein, osteolytic bony lesions, hypercalcemia and diffuse bone marrow involvement favor a diagnosis of PBM. In contrast, EBER expression in neoplastic cells, HIV coinfection and high proliferative index support a diagnosis of PBL. When myeloma-defining signs are incomplete or absent, the presence of oropharyngeal soft tissue lesion or lymphadenopathy favor a diagnosis of PBL, regardless of bone marrow disease. The distinction is very important as the treatment of these entities differ remarkably. PBL is an aggressive disease with relapsing clinical course and has higher rates of disease progression and fatality despite use of state of the art treatment modalities. Current guidelines recommend intensive regimens such as EPOCH (infusional etoposide, vincristine, doxorubicin with bolus cyclophosphamide and prednisolone) and Hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone alternating with methotrexate and cytarabine). On the other hand, myeloma is managed with Bortezomib-based regimens followed by autologous stem cell transplantation (ASCT). Despite extensive work-up, few cases remain to be classified into any of the two categories and thus are labelled as Indeterminate [2, 3]. We present one such case with overlapping features thereby making the diagnosis very intriguing. …
Literatur
1.
Zurück zum Zitat Harmon CM, Smith LB (2016) Plasmablastic lymphoma a review of clinicopathologic features and differential diagnosis. Arch Pathol Lab Med 140:1074–1078CrossRefPubMed Harmon CM, Smith LB (2016) Plasmablastic lymphoma a review of clinicopathologic features and differential diagnosis. Arch Pathol Lab Med 140:1074–1078CrossRefPubMed
2.
Zurück zum Zitat Ahn JS, Okal R, Vos JA et al (2017) Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma. J Clin Pathol 70(9):775–780CrossRefPubMed Ahn JS, Okal R, Vos JA et al (2017) Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma. J Clin Pathol 70(9):775–780CrossRefPubMed
3.
Zurück zum Zitat Castillo JJ, Bibas M, Miranda RN (2015) The biology and treatment of plasmablastic lymphoma. Blood 125:2323–2330CrossRefPubMed Castillo JJ, Bibas M, Miranda RN (2015) The biology and treatment of plasmablastic lymphoma. Blood 125:2323–2330CrossRefPubMed
4.
Zurück zum Zitat Chang ST, Liao YL, Lu CL et al (2007) Plasmablastic cytomorphologic features in plasma cell neoplasms in immunocompetent patients are significantly associated with EBV. Am J Clin Pathol 128:339–344CrossRefPubMed Chang ST, Liao YL, Lu CL et al (2007) Plasmablastic cytomorphologic features in plasma cell neoplasms in immunocompetent patients are significantly associated with EBV. Am J Clin Pathol 128:339–344CrossRefPubMed
Metadaten
Titel
Plasmablastic Lymphoma Versus EBV-Positive Myeloma
verfasst von
Divya Bansal
Neha Singh
Narendra Agrawal
Anurag Mehta
Publikationsdatum
15.03.2019
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 3/2019
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-019-01116-7

Weitere Artikel der Ausgabe 3/2019

Indian Journal of Hematology and Blood Transfusion 3/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.